Lymphoma Cancer | Tumor

CURE’s lymphoma cancer page is a go-to resource for oncology news and updates in the world of lymphoma cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in lymphoma cancer.

FDA Approval of Jakafi for Chronic GVHD Provides Another Option, But ‘More Work Needs to Be Done’

September 29th 2021

While the recent FDA approval of Jakafi offers another effective option for patients with chronic GVHD, one expert urges that more work needs to be done to prevent and/or reverse the condition.

Outcome Disparities Persist in Young Patients With Hodgkin Lymphoma

September 28th 2021

Certain races/ethnicities and ages may have worse outcomes in Hodgkin lymphoma regardless of variation in upfront chemotherapy.

New Book Written By Former Pediatric Oncologist Emphasizes Patients With Cancer ‘Are Not Alone’

September 22nd 2021

The tome also reflects on his own diagnosis of cancer and how it influenced his practice.

FDA Approves Jakafi for Chronic GVHD

September 22nd 2021

The FDA has granted approval to Jakafi (ruxolitinib) for the treatment of chronic graft-versus-host disease (GVHD).

Chronic GVHD Treatment Improves, But Is Still Far From Perfect

September 20th 2021

Patients with blood cancer who underwent stem cell transplant and developed chronic graft-versus-host disease have more treatment options than ever before. But the formula for planning older and newer therapies has not yet been established.

Jeff Bridges Announces Remission From Lymphoma, Cancer Survivor Becomes Runway Model and More

September 17th 2021

From Jeff Bridges achieving remission from cancer to a cancer survivor who became a runway model, here’s what’s happening in the cancer landscape this week.

FDA Approves Brukinsa for Marginal Zone Lymphoma Treatment

September 15th 2021

Patients with relapsed/refractory, pretreated marginal zone lymphoma are now eligible for treatment with Brukinsa.

Can a Blood Test Predict Lymphoma Relapse?

September 3rd 2021

Circulating tumor DNA found in blood plasma may help predict if the likelihood of relapse for patients with large B-cell lymphoma, according to recent research.

Patients With Blood Cancers and COVID-19 May Benefit From Convalescent Plasma Therapy

September 2nd 2021

The use of convalescent plasma therapy in patients with blood cancers and COVID-19 was associated with an improvement in survival from the infection.

Brukinsa Receives FDA Approval for Treatment of Waldenstrom’s Macroglobulinemia

September 1st 2021

The FDA approval of Brukinsa, according to an expert from the Dana-Farber Cancer Institute, provides an important new option for targeted therapy in Waldenstrom’s macroglobulinemia.

Caring for a Patient With Lymphoma Also Includes the Caregiver

September 1st 2021

A recent webinar from the Lymphoma Research Foundation gave important advice for caregivers, including the importance of taking care of oneself.

Blood Cancer Survivors Should Not Rely on COVID-19 Antibody Tests to Determine Immunity

August 24th 2021

Patients with blood cancers may be less likely to derive immunity from the COVID-19 vaccine, though antibody tests should not be the end-all-be-all in guiding their behavior.

Investigational Cancer Treatment Being Evaluated in B-Cell Malignancies

August 23rd 2021

Researchers are evaluating the safety and efficacy of zandelisib, an investigational cancer therapy, for the treatment of patients with marginal zone lymphoma and follicular lymphoma who have received at least two prior therapies.

Drug Combo Provides Clinical Benefit With Fewer Side Effects in B-Cell Lymphoma

August 20th 2021

Combining PI3 kinase inhibitors with BTK inhibitors can mitigate side effects traditionally seen with PI3 kinase inhibitors, according to recent research.

The Olympic Silver Medalist Who Survived Cancer: Kevin McDowell Shares His Story

August 19th 2021

In this episode of the “CURE® Talks Cancer” podcast, Olympic triathlete Kevin McDowell discusses his cancer journey and shares some insight on his experiences at the Tokyo 2020 Olympics.

AYA Patients Are Represented in Clinical Trials, But Survival Outcomes Still Lag

August 12th 2021

Adolescent and young adult patients are more represented than previously expected in clinical trials. However, their outcomes still lag behind the younger and older populations.

Long-Term Pain Management in Blood Cancers: When Are Opioids Appropriate?

August 9th 2021

Blood cancer survivors are living longer than ever, making safe pain management an important concern.

Never Back Down: Lymphoma Survivor Stays Positive

August 6th 2021

In his new memoir, a patient with central nervous system lymphoma emphasizes the importance of a positive mindset and a strong support system.

Survivor Offers 5 Tips on Becoming Your Own Advocate

August 3rd 2021

Nina Luker, a healthy 25 year old, felt invincible. But she says that "naïve perspective was disrupted in a matter of hours."

Pregnant Women With Previous or Current Cancer Diagnoses May Experience More Complications During Delivery

August 2nd 2021

Pregnant women who had cancer previously or currently have cancer were more likely to experience comorbidities and in-hospital complications, depending on cancer type.

Patients With Blood Cancer Less Likely to Produce COVID-19 Antibodies After Vaccination

July 26th 2021

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

90-Year-Old Will Walk 3,600 Miles for Children With Cancer, KISS and Cinderella Keyboardist Dies From Cancer and More

July 23rd 2021

From a 90-year-old man’s 3,600-mile walk to raise money for children with cancer to the death of KISS and Cinderella keyboardist Gary Corbett, here’s what’s happening in the cancer landscape this week.

FDA Approval of Rylaze ‘Fulfills an Unmet Need’ for Group of Patients With Leukemia and Lymphoma

July 21st 2021

The FDA approval of Rylaze provides certain patients with leukemia and lymphoma with an on-demand treatment option since the only other approved therapy is currently undergoing a shortage.

Combination Therapy May Provide New Treatment Option for Patients with Lymphoma

June 23rd 2021

Monjuvi and Revlimid attained extended remission and improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma.

Immunotherapy Options Around the Bend

June 18th 2021

One expert tells patients to ‘hang tight’ as immunotherapy options are getting better each year.

Yescarta Associated With Better Outcomes Than Other Available Treatments for Relapsed/Refractory Follicular Lymphoma

June 14th 2021

These findings, according to one of the study’s authors, demonstrate that Yescarta addresses an important unmet medical need for patients with relapsed/refractory follicular lymphoma.

Learning to Live with an Incurable, Inoperable Cancer

June 10th 2021

In this episode of the “CURE® Talks Cancer” podcast, author Steve Kelley shares both the painful and positive moments of his journey with a rare cancer.

Novel Triplet Combination Shows ‘Notable Efficacy in a Challenging to Treat’ Population of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

June 6th 2021

Treatment with the combination of Polivy, rituximab and lenalidomide safely conferred responses in patients with relapsed/refractory diffuse large B-cell lymphoma, with most patients still in remission at the study’s cutoff date.

Aliqopa Plus Rituximab Improves Survival for Relapsed Non-Hodgkin Lymphoma

June 3rd 2021

Combination therapy with Aliqopa and rituximab improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma.

CURE’s Clinical Trial Corner: May 2021

May 27th 2021

As the cancer treatment landscape continues to expand, patients and their caregivers should be aware of the various clinical trials currently being conducted — including studies they can possibly join.